{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:19:35Z","timestamp":1761506375650,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cllc.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T19:19:05Z","timestamp":1685819945000},"page":"519-527.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-5315","authenticated-orcid":false,"given":"Kimio","family":"Yonesaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruko","family":"Daga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akito","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.05.008_bib0001","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0002","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0003","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cllc.2023.05.008_bib0004","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0005","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0006","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0007","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cllc.2023.05.008_bib0008","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2023.05.008_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lungcan.2021.08.007","article-title":"A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632","volume":"161","author":"Noro","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.05.008_bib0010","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2023.05.008_bib0011","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2023.05.008_bib0012","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0014","doi-asserted-by":"crossref","first-page":"VIII741","DOI":"10.1093\/annonc\/mdy424.064","article-title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0016","first-page":"1059","article-title":"Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR-mutant Ba\/F3 cells","volume":"41","author":"Yonesaka","year":"2019","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cllc.2023.05.008_bib0017","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/onc.2015.142","article-title":"Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib","volume":"35","author":"Yonesaka","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2023.05.008_bib0018","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cllc.2023.05.008_bib0019","doi-asserted-by":"crossref","first-page":"33602","DOI":"10.18632\/oncotarget.5286","article-title":"The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer","volume":"6","author":"Yonesaka","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2023.05.008_bib0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0021","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2022.04.004","article-title":"Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: a single-group, open-label phase 2 trial (WJOG10818L)","volume":"168","author":"Hayashi","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.05.008_bib0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lungcan.2019.03.030","article-title":"A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)","volume":"135","author":"Yokoyama","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.05.008_bib0023","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s10147-021-01947-3","article-title":"CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib","volume":"26","author":"Kato","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLOS Comput Biol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0026","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1038\/s41598-019-55939-5","article-title":"Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors","volume":"9","author":"Yonesaka","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2023.05.008_bib0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0028","doi-asserted-by":"crossref","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0029","doi-asserted-by":"crossref","first-page":"58492","DOI":"10.18632\/oncotarget.11303","article-title":"Detection of the T790M mutation of EGFR in plasma of advanced non\u2013small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)","volume":"7","author":"Takahama","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2023.05.008_bib0030","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2023.05.008_bib0031","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung Cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2023.05.008_bib0032","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2012.45.0981","article-title":"LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both","volume":"31","author":"Katakami","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0033","doi-asserted-by":"crossref","first-page":"68123","DOI":"10.18632\/oncotarget.19243","article-title":"Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor\u2013na\u00efve patients with non\u2013small cell lung cancer harboring EGFR mutations","volume":"8","author":"Tanaka","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2023.05.008_bib0034","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tranon.2019.04.004","article-title":"Comparison of T790M acquisition between patients treated with afatinib and gefitinib as first-line therapy: retrospective propensity score matching analysis","volume":"12","author":"Yoon","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0035","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2023.05.008_bib0036","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non\u2013small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2023.05.008_bib0037","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2023.05.008_bib0038","doi-asserted-by":"crossref","first-page":"eaan6566","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cllc.2023.05.008_bib0039","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0040","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M\u2013positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0041","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment Strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2023.05.008_bib0042","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s43018-022-00351-8","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.cllc.2023.05.008_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657283","article-title":"Efficacy and resistance of afatinib in Chinese non-small cell lung cancer patients with HER2 alterations: a multicenter retrospective study","volume":"11","author":"Song","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0044","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-014-2403-2","article-title":"Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors","volume":"73","author":"Freiwald","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0045","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-20-4465","article-title":"Thirty years of HER3: from basic biology to therapeutic interventions","volume":"27","author":"Haikala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2023.05.008_bib0046","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/JTO.0b013e3182781e35","article-title":"Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Kobayashi","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0047","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/15384047.2016.1139235","article-title":"Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma","volume":"17","author":"Kim","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.cllc.2023.05.008_bib0048","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/JTO.0b013e3181e8b3c5","article-title":"Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer","volume":"5","author":"Hata","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0049","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-15-1046","article-title":"EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs","volume":"21","author":"Kobayashi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2023.05.008_bib0050","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.2147\/OTT.S118071","article-title":"Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer","volume":"9","author":"Wu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2023.05.008_bib0051","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2020.38.15_suppl.9507","article-title":"Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"38","author":"Rotow","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100271","article-title":"Osimertinib plus platinum\u2013pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced\/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study","volume":"6","author":"Planchard","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2023.05.008_bib0053","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1016\/j.jtho.2021.01.1130","article-title":"P76. 73 MARIPOSA: randomized phase 3 study of first-line amivantamab+ lazertinib vs osimertinib vs lazertinib in EGFR-mutant NSCLC","volume":"16","author":"Shreeve","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.05.008_bib0054","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:54Z","timestamp":1761506094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1525730423001109"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.05.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}